Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.4800 +0.1100 (+8.03%) 04/04/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.4700 -0.0100 (-0.68%) 19:39 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2600
Day High
1.4900
Open 1.3500
Previous Close 1.3700 1.3700
Volume 5,310,900 5,310,900
Avg Vol 4,117,655 4,117,655
Stochastic %K 8.69% 8.69%
Weighted Alpha -90.92 -90.92
5-Day Change -0.2300 (-13.45%) -0.2300 (-13.45%)
52-Week Range 1.2600 - 10.5000 1.2600 - 10.5000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 308,284
  • Shares Outstanding, K 225,025
  • Annual Sales, $ 0 K
  • Annual Income, $ -266,760 K
  • EBIT $ -273 M
  • EBITDA $ -255 M
  • 60-Month Beta 1.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 160.48% ( -218.78%)
  • Historical Volatility 124.81%
  • IV Percentile 53%
  • IV Rank 12.09%
  • IV High 833.42% on 01/06/25
  • IV Low 67.95% on 10/07/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 362
  • Volume Avg (30-Day) 903
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 24,321
  • Open Int (30-Day) 26,062

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.21
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.24
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +34.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +17.46%
on 04/04/25
Period Open: 2.5600
3.0050 -50.75%
on 03/17/25
-1.0800 (-42.19%)
since 03/04/25
3-Month
1.2600 +17.46%
on 04/04/25
Period Open: 1.7100
7.3000 -79.73%
on 01/08/25
-0.2300 (-13.45%)
since 01/03/25
52-Week
1.2600 +17.46%
on 04/04/25
Period Open: 8.5100
10.5000 -85.90%
on 05/06/24
-7.0300 (-82.61%)
since 04/04/24

Most Recent Stories

More News
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

SANA : 1.4800 (+8.03%)
MLYS : 12.40 (-8.35%)
AEON : 0.4660 (-12.32%)
Sana: Q4 Earnings Snapshot

Sana: Q4 Earnings Snapshot

SANA : 1.4800 (+8.03%)
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SANA : 1.4800 (+8.03%)
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

SANA : 1.4800 (+8.03%)
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

KAPA : 1.0600 (+12.77%)
SANA : 1.4800 (+8.03%)
SLXN : 0.8627 (-8.22%)
AEON : 0.4660 (-12.32%)
CRGX : 4.02 (-1.95%)
There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

AVDL : 6.80 (-5.56%)
SANA : 1.4800 (+8.03%)
IBB : 117.16 (-5.36%)
ADMA : 18.01 (-7.40%)
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.

With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.

$SPX : 5,074.08 (-5.97%)
SANA : 1.4800 (+8.03%)
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental...

CTMX : 0.4556 (-16.11%)
CSTL : 18.57 (-3.23%)
SANA : 1.4800 (+8.03%)
HALO : 59.77 (-3.47%)
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SANA : 1.4800 (+8.03%)
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement

Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field.

SANA : 1.4800 (+8.03%)
S&P Futures Slip on Trump Tariff Worries, U.S. ADP Jobs Report and FOMC Minutes in Focus

March S&P 500 E-Mini futures (ESH25) are trending down -0.27% this morning as investors weighed concerns over U.S. tariffs while awaiting the Federal Reserve’s December meeting minutes, comments from...

MSTR : 293.61 (+4.01%)
CALM : 92.29 (-0.73%)
SHEL.LN : 2,490.821 (-6.62%)
PLX.FP : 17.948 (-2.87%)
SANA : 1.4800 (+8.03%)
RGTI : 7.50 (-7.98%)
ESH25 : 5,617.80s (-0.79%)
QUBT : 6.51 (-14.00%)
TSLA : 239.43 (-10.42%)
QBTS : 6.34 (-11.45%)
AMD : 85.76 (-8.57%)
EQT.S.DX : 258.700 (-11.80%)
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

SANA : 1.4800 (+8.03%)
Sana Biotechnology Receives FDA Fast Track Designation for SC291 in Treatment of Relapsed/Refractory Systemic Lupus Erythematosus

Sana Biotechnology's SC291 receives FDA Fast Track designation for treating relapsed/refractory systemic lupus erythematosus, with initial data expected in 2025.Quiver AI SummarySana Biotechnology, Inc....

SANA : 1.4800 (+8.03%)
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

SANA : 1.4800 (+8.03%)
Sana Biotechnology to Present at December 2024 Investor Conferences

SANA : 1.4800 (+8.03%)
Sana: Q3 Earnings Snapshot

Sana: Q3 Earnings Snapshot

SANA : 1.4800 (+8.03%)
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

SANA : 1.4800 (+8.03%)
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

SANA : 1.4800 (+8.03%)
Sana: Q2 Earnings Snapshot

Sana: Q2 Earnings Snapshot

SANA : 1.4800 (+8.03%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 11.78 (-7.90%)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 11.78 (-7.90%)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 11.78 (-7.90%)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 11.78 (-7.90%)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 11.78 (-7.90%)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 11.78 (-7.90%)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?

Good news drove shares of these stocks through the roof last week, but investors should be more concerned about their paths forward.

COMP : 8.28 (-1.78%)
SANA : 1.4800 (+8.03%)
BKD : 5.81 (-7.19%)
Why Shares of Sana Biotechnology Jumped This Week

The company announced details of research on two of its pre-clinical therapies.

SANA : 1.4800 (+8.03%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 11.78 (-7.90%)
EVLO : 0.0005 (unch)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where Needed

Flagship Pioneering, the bioplatform innovation company, today unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the...

DNLI : 11.78 (-7.90%)
EVLO : 0.0005 (unch)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines...

CRL : 136.90 (-2.89%)
DNLI : 11.78 (-7.90%)
EVLO : 0.0005 (unch)
FHTX : 3.44 (+9.21%)
MRNA : 25.11 (-2.41%)
OMGA : 0.1426 (-10.82%)
SANA : 1.4800 (+8.03%)
MCRB : 0.6400 (-6.92%)

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 1.7900
2nd Resistance Point 1.6400
1st Resistance Point 1.5600
Last Price 1.4800
1st Support Level 1.3300
2nd Support Level 1.1800
3rd Support Level 1.1000

See More

52-Week High 10.5000
Fibonacci 61.8% 6.9703
Fibonacci 50% 5.8800
Fibonacci 38.2% 4.7897
Last Price 1.4800
52-Week Low 1.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades